| A prospective randomized controlled clinical trial comparing the effects of somatostatin and vasopressin for control of acute variceal bleeding in the patients with liver cirrhosis. | |
| | |
MedLine Citation:
|
PMID: 14619385 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Acute variceal bleeding is a serious complication of liver cirrhosis, which has an attendant mortality of approximately 60% over two years, and a variety of treatments, such as balloon tamponade, endoscopic varix ligation, sclerotherapy, histoacryl injection and vasoactive drugs, have been used. The aims of the present trial were to compare the effectiveness and complications of somatostatin and vasopressin in the treatment of acute variceal bleeding. METHODS: Forty-three cirrhotic patients, with endoscopically proven acute variceal bleeding, were included in this trial. Both drugs were given as continuous intravenous infusions for 48 hours. Twenty patients received the somatostatin (250 mcg per hr after a bolus of 50 mcg) and twenty-three the vasopressin (0.4 units per min). RESULTS: There were no significant differences between the two groups in relation to age, sex, etiology of cirrhosis, Child-Pugh classification, characteristics of bleeding episode, laboratory findings before randomization and units of transfused blood during therapy. Rebleeding, within 6 hours after beginning of therapy, was regarded as failure to control initial bleeding, and was observed in 3 (13.0%) of the patients who received vasopressin and in 1 (5.0%) treated with somatostatin (p > 0.05). Five patients in both the somatostatin (25.0%) and vasopressin (21.7%) groups rebled during the first 5 days following the initial therapy (p > 0.05). Meaningful complications related to the use of vasopressin were observed in 5 patients (chest pain or abdominal pain requiring nitroglycerin), but no complications were associated with the use of somatostatin (p < 0.05). The mortalities during hospitalization were similar in both the treatment groups. Two of the vasopressin and 1 of the somatostatin group died due to the uncontrolled rebleeding, and 1 of the vasopressin group died due to hepatic failure (2 weeks later after therapy). CONCLUSION: This study showed no differences in the effectiveness of somatostatin and vasopressin, but the somatostatin group had a lower risk of the complications. |
| | |
Authors:
|
Heon Young Lee; Heon Ju Lee; Seung Min Lee; Jun Hwan Kim; Soon Wook Kweon; Byung Seok Lee; Nam Jae Kim |
Related Documents
:
|
3198005 - Recurrent bleeding from cutaneous venous collaterals in portal hypertension. 20362285 - The safety and probable therapeutic effect of routine use of antibiotics and simultaneo... 9861375 - Prognostic significance of clinical grading of patients envenomed by bothrops lanceolat... 3497685 - Injection sclerotherapy in adult patients with extrahepatic portal venous obstruction. 3772785 - The role of 1% sodium hyaluronate in treating vitreous incarceration with the neodymium... 20934655 - Bare nitinol stent enabled recanalization of long-segment, chronic total occlusion of s... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: The Korean journal of internal medicine Volume: 18 ISSN: 1226-3303 ISO Abbreviation: Korean J. Intern. Med. Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-11-17 Completed Date: 2004-01-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712418 Medline TA: Korean J Intern Med Country: Korea (South) |
Other Details:
|
Languages: eng Pagination: 161-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea. leehy@hanbat.chungnam.ac.kr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Esophageal and Gastric Varices
/
drug therapy*,
etiology Female Gastrointestinal Hemorrhage / drug therapy*, etiology Hemostatics / administration & dosage*, adverse effects Humans Infusions, Intravenous Liver Cirrhosis / complications*, mortality, therapy Male Middle Aged Prospective Studies Somatostatin / administration & dosage*, adverse effects Treatment Outcome Vasopressins / administration & dosage*, adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Hemostatics; 11000-17-2/Vasopressins; 51110-01-1/Somatostatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneo...
Next Document: The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina...